<DOC>
	<DOC>NCT02151110</DOC>
	<brief_summary>Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920</brief_summary>
	<brief_title>A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults</brief_title>
	<detailed_description />
	<criteria>Healthy as determined by a responsible study physician based on medical evaluation Body weight 40 to 100 kg Body mass index 19.0 to 30.0 kg/m2 History of allergy or sensitivity to Shellfish or protein based antigens previous immunization with KLH previous splenectomy History of diagnosed or suspected thromboembolic event or coagulation disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy Male</keyword>
	<keyword>Healthy Female of non child bearing potential</keyword>
</DOC>